Aller au contenu principal
Profil bibliographique

Yen‐Hao Chen

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

119Publications signalées
2316Citations signalées
2Affiliations récentes

Les institutions déclarées

Les domaines associés

Esophageal Cancer Research and TreatmentHepatocellular Carcinoma Treatment and PrognosisEsophageal and GI PathologyHead and Neck Cancer StudiesGastric Cancer Management and Outcomes

Les publications récentes

Accès ouvert 2026 article OpenAlex

Neoadjuvant Treatment Including Targeted Therapy and Locoregional Interventions for Locally Advanced Thyroid Cancer: A Single-Center Retrospective Cohort Study

Tz-You Chen, Lay San Lim, Yen‐Hao Chen, Yi‐Chia Chan et autres

Background: Locally advanced thyroid cancer is associated with a poor prognosis and high surgical morbidity. This study evaluated the feasibility and outcomes of neoadjuvant treatment including targeted therapy with locoregional interventions. Methods: We retrospectively analyzed 17 patients with locally advanced thyroid cancer …

tw (code pays fourni par la source)

0 citations Cancers
Accès ouvert 2026 article OpenAlex

Radium-223 Treatment Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer: A Taiwan-Japan Collaborative Cohort Study

Hao‐Lun Luo, Yi Yang Liu, Hui Ying Liu, Yu Li Su et autres

BACKGROUND: This study examined oncologic outcomes associated with Radium-223 (Ra-223) administered at different treatment lines in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, and evaluated the prognostic implications of biomarker responses-particularly prostate-specific antigen (PSA) and alkaline phosphatase (ALP)-during Ra-223 …

tw, jp (code pays fourni par la source)

0 citations Biomedical Journal
Accès ouvert 2025 article OpenAlex

Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis

Yuan‐Hung Kuo, Wei Teng, Yen‐Hao Chen, Po‐Ting Lin et autres

Background and Aims: The prognostic nutritional index (PNI), calculated from serum albumin and lymphocyte count, reflects a patient's immune-nutritional status and has been proposed as a prognostic marker in hepatocellular carcinoma (HCC). However, its role in advanced HCC patients treated with atezolizumab …

tw (code pays fourni par la source)

1 citation Journal of Clinical and Translational Hepatology
Accès ouvert 2025 article OpenAlex

Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis

Yuan‐Hung Kuo, Wei Teng, Po‐Ting Lin, Yen‐Hao Chen et autres

INTRODUCTION: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality, particularly in patients with advanced stage. Atezolizumab plus bevacizumab (Ate/Bev) is the standard first-line therapy; however, its efficacy may be further enhanced using combination strategies. METHODS: This study evaluated the clinical …

tw (code pays fourni par la source)

1 citation Liver International
Accès ouvert 2025 article OpenAlex

Intensity-Modulated Proton Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Chieh-Min Liu, Chia‐Hsuan Lai, Yu‐Ming Wang, Eng-Yen Huang et autres

Background: Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) have poor outcomes and limited treatment options. Clinical data specifically evaluating the effects of intensity-modulated proton therapy (IMPT) for this population remain scarce. We reported the outcomes of patients with …

tw (code pays fourni par la source)

0 citations Journal of Hepatocellular Carcinoma
Accès ouvert 2025 article OpenAlex

Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan

Ching-Di Chang, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang et autres

Background/Aims: Muscle volume loss (MVL) is associated with poor outcomes in patients with hepatocellular carcinoma (HCC). However, dynamic muscle atrophy during HCC treatment is also a critical concern. This study aimed to determine the clinical significance of MVL and severe muscle atrophy …

tw (code pays fourni par la source)

0 citations Gut and Liver
Accès ouvert 2025 article OpenAlex

Multicenter, international, retrospective study of prognostic factors for Ra223

Takuya Oishi, Hao‐Lun Luo, Yoshiomi Hatayama, Hideo Kawaguchi et autres

The risk factors for adium-233 dichloride (Ra223) treatment on prognosis remain unclear. We aimed to validate the risk model for a radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively evaluated 345 patients with bone …

jp, tw (code pays fourni par la source)

0 citations Scientific Reports
Accès ouvert 2025 article OpenAlex

Clinical outcomes of dabrafenib plus trametinib in locally advanced or metastatic BRAF V600E-mutant papillary thyroid cancer

Yen‐Hao Chen

BRAF V600E is the most common oncogenic mutation in papillary thyroid carcinoma (PTC). This study aimed to assess the clinical outcomes of combining dabrafenib and trametinib in patients with BRAF V600E-mutant PTC. Patients with BRAF V600E-mutant PTC treated with dabrafenib and trametinib …

tw (code pays fourni par la source)

1 citation American Journal of Cancer Research
Accès ouvert 2024 article OpenAlex

Aldo-keto reductase family 1 member B10 prevents esophageal squamous cell carcinoma from reactive carbonyl species-induced cell death and promotes its progression

Shau-Hsuan Li, Wan‐Ting Huang, Yen‐Hao Chen, Hung‐I Lu et autres

INTRODUCTION: Chronic alcohol consumption and tobacco usage are major risk factors for esophageal squamous cell carcinoma (ESCC). Excessive tobacco and alcohol consumption lead to oxidative stress and the generation of reactive carbonyl species (RCS) which induce DNA damage and cell apoptosis. This …

tw (code pays fourni par la source)

3 citations Cancer Cell International
Accès ouvert 2024 article OpenAlex

Hypoalbuminemia is Associated with Higher 90-Day Mortality and Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma and Liver Cirrhosis Receiving Radiotherapy-Based Therapy

Yu-Yang Hua, Ming‐Chun Kuo, Yen‐Hao Chen, Hung‐I Lu et autres

Background: Liver cirrhosis (LC) is common among patients with esophageal squamous cell carcinoma (ESCC) due to shared etiologic factor, alcohol. For non-metastatic ESCC (nmESCC) patients with cirrhosis, surgery is often contraindicated or associated with high morbidity, therefore radiotherapy-based therapy was commonly applied. …

tw (code pays fourni par la source)

3 citations Cancer Management and Research
Accès ouvert 2024 article OpenAlex

Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy

Kuan-Chang Lai, Yen‐Hao Chen, Yi-Ping Hung, Nai-Jung Chiang et autres

BACKGROUND/PURPOSE: Recently, anti-programmed cell death protein-1 (anti-PD-1) and anti-PD-L1 therapies were approved for hepatocellular carcinoma (HCC). However, the effectiveness of rechallenging with one immune checkpoint inhibitor (ICI) after failure of another remains unclear. This study explores the efficacy and safety of anti-PD-L1 …

tw (code pays fourni par la source)

17 citations Hepatology International
Accès ouvert 2024 article OpenAlex

The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

Yuyin Liu, Ming-Yen Tsai, Tingting Liu, Yueh-Wei Liu et autres

BACKGROUND: The aim of this study is to investigate the real-world efficacy and safety of nivolumab in combination with chemotherapy for patients with advanced human epidermal growth factor receptor 2 (HER2)-negative gastric cancer (GC). METHODS: We enrolled patients diagnosed with unresectable advanced …

tw (code pays fourni par la source)

2 citations BMC Cancer

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.